Cipher Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cipher Pharmaceuticals Inc.
More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.
2023 saw a number of gene therapy companies go to the wall, but those that can combine clinical significance and commercial success can build sustainable businesses.
After years of laying the foundations, China Biotech Inc. is being pursued by multinationals looking for innovative candidates to commercialize in both China and globally, executives and deals from the just concluded J.P Morgan Global Healthcare Conference show.
Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Innocutis Medical LLC (Innocutis Holding LLC
- JSJ Pharmaceuticals)
- Cipher Pharmaceuticals US LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.